Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dimitrios-Ioannis Kasartzian has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Transforming Cardiovascular Risk Prediction: A Review of Machine Learning and Artificial Intelligence Innovations

    by Dimitrios-Ioannis Kasartzian, Thomas Tsiampalis

    Cardiovascular diseases (CVDs) remain a leading cause of global mortality and morbidity. Traditional risk prediction models, while foundational, often fail to capture the multifaceted nature of risk factors or leverage the expanding pool of healthcare data. Machine learning (ML) and artificial intelligence (AI) approaches represent a paradigm shift in risk prediction, offering dynamic, scalable solutions that integrate diverse data types. This review examines advancements in AI/ML for CVD risk prediction, analyzing their strengths, limitations, and the challenges associated with their clinical integration. Recommendations for standardization, validation, and future research directions are provided to unlock the potential of these technologies in transforming precision cardiovascular medicine.


  • The role of soluble urokinase plasminogen activator receptor (suPAR) in patients with cancer: a review of the current literature

    by Themistoklis Paraskevas, Francesk Mulita, Christos Michailides, Georgios-Ioannis Verras, Elias Liolis, Eleousa Oikonomou, Ioannis Perdikaris, Panagiotis Perdikaris, Konstantinos Bouchagier, Ioannis Panagiotopoulos, et al.

    Aim Several biomarkers are currently used as diagnostic and prognostic tools in patients with cancer. Soluble urokinase plasminogen activator receptor (suPAR) is elevated in acute and chronic inflammatory procedures and several observational studies during the last 20 years have investigated its role in oncology. The purpose of this article was to review the current literature regarding suPAR’s role in clinical practice.Methods A systematic literature search of PubMed, Scopus, OpenGrey and Cochrane Library databases through September2021 was conducted using the following search terms: “supar” or “soluble urokinase plasminogen receptor” and “cancer” or “malignancy”. Original articles reporting on suPAR’s role in the diagnosis, prognosis and prediction of therapeutic outcomes in patients with confirmed or suspected cancer were included.Results Among 45 found articles, the most were observational cohort studies. The included studies were further categorized bycancer site. SuPAR level was higher in patients with cancer compared to healthy controls, but its diagnostic and prognostic accuracy differs depending on the site of cancer.Conclusion SuPAR has promising aspects in the field of oncology and public health and future research should further investigateits use in clinical practice. As it is elevated in different types of cancer, it could potentially serve as an adjunctive tool for the mass screening of patients with non-specific signs of cancer, but larger cohort studies that support these findings must be conducted.


  • Procalcitonin and sepsis in the Emergency Department: an update

    by D. Velissaris, N. Zareifopoulos, M. Lagadinou, C. Platanaki, K. Tsiotsios, E. L. Stavridis, D. Kasartzian, C. Pierrakos, V Karamouzos

    OBJECTIVE: Due to significant mortality and morbidity which may be reduced by prompts treatment. there is great interest in determining an ideal biomarker for the diagnosis of sepsis upon presentation to the Emergency Department. The most specific test is a positive blood culture. but its sensitivity is very low, and the results are usually available 2 days after sampling. For this reason, research is conducted into serum biomarkers with greater sensitivity for which results can be available within hours of presentation. High initial procalcitonin levels are a sensitive marker of bacterial infection, and the degree of procalcitonin elevation may determine which patients are at greater risk for adverse outcomes (mortality or ICU admission). The purpose of this narrative review is to evaluate the utility of procalcitonin as a diagnostic marker of sepsis in the emergency department and the use of procalcitonin-guided management algorithms. MATERIALS AND METHODS: A PubMed search was conducted in June 2020 for procalcitonin, resulting in the retrieval of 371 articles which were screened for relevance. 48 articles were included in the review. CONCLUSIONS: Procalcitonin elevation may be used as an indication for initiation of antibiotic treatment, and antibiotics may be discontinued once procalcitonin normalizes. This approach leads to reduced antibiotic consumption, but it is not yet clear whether it ensures better outcomes for patients. Procalcitonin in centers where it is available could be a useful diagnostic and prognostic biomarker for patients presenting to the Emergency Department with symptoms suggestive of sepsis. Further research is however required to determine whether the use of procalcitonin measurements in management algorithms leads to improved patient outcomes.